Key Clinical Trials in Erectile Dysfunction

Cover -- Contents -- 1. The Earliest Carefully Controlled Clinical Trial Evaluating Oral Pharmacotherapy (Yohimbine) in ED -- 1.1 Key Trial References -- 1.2 Importance of Study -- 1.3 Study Design -- 1.4 Key Results -- 1.5 Conclusions from Original Reports -- 1.6 Strengths -- 1.7 Weaknesses -- 1.8 Relevance -- 2. A Description of the Pioneering Work That Led to the First Approved Agents for ED: Giles Brindley, the Needle, and the Penis (Phenoxybenzamine) -- 2.1 Key Trial References -- 2.2 Importance of Study -- 2.3 Study Design -- 2.4 Key Results -- 2.5 Conclusions from Original Reports -- 2.6 Strengths -- 2.7 Weaknesses -- 2.8 Relevance -- 3. The Pivotal Study Showing That Intracorporal Injection of Vasoactive Agents (Papaverine or Phenoxybenzamine) Was Effective Pharmacotherapy -- 3.1 Key Trial References -- 3.2 Importance of Study -- 3.3 Study Design -- 3.4 Key Results -- 3.5 Conclusions from Original Reports -- 3.6 Strengths -- 3.7 Weaknesses -- 3.8 Relevance -- 4. The First Placebo-Controlled Study on the Benefits of Intracorporal Administration of Vasorelaxant Agents to ED Patients (Papaverine/Phentolamine Combination) -- 4.1 Key Trial References -- 4.2 Importance of Study -- 4.3 Study Design -- 4.4 Key Results -- 4.5 Conclusions from Original Reports -- 4.6 Strengths -- 4.7 Weaknesses -- 4.8 Relevance -- 5. Representative Study on the Use of Yohimbine in the Treatment of Organic ED -- 5.1 Key Trial References -- 5.2 Importance of Study -- 5.3 Study Design -- 5.4 Key Results -- 5.5 Conclusions from Original Reports -- 5.6 Strengths -- 5.7 Weaknesses -- 5.8 Relevance -- 6. Defining the Therapeutic Ratio for Intracavernosal Administration of Prostaglandin E1 (Alprostadil) -- 6.1 Key Trial References -- 6.2 Study Funding -- 6.3 Importance of Study -- 6.4 Study Design -- 6.5 Key Results -- 6.6 Conclusions from Original Reports -- 6.7 Strengths -- 6.8 Weaknesses -- 6.9 Relevance -- 7. An Elegant Long-Term Trial Assessing the Clinical Profile of Intracavernosal Prostaglandin E1 (Alprostadil) -- 7.1 Key Trial References -- 7.2 Importance of Study -- 7.3 Study Design -- 7.4 Key Results -- 7.5 Conclusions from Original Reports -- 7.6 Strengths -- 7.7 Weaknesses -- 7.8 Relevance -- 8. Evaluation of Novel Combination (Vasoactive Intestinal Polypeptide and Phentolamine) as Intracavernosal Therapy -- 8.1 Key Trial References -- 8.2 Study Funding -- 8.3 Importance of Study -- 8.4 Study Design -- 8.5 Key Results -- 8.6 Conclusions from Original Reports -- 8.7 Strengths -- 8.8 Weaknesses -- 8.9 Relevance -- 9. Now-Classic Study on the Use of Intraurethral Prostaglandin E1 (Alprostadil) -- 9.1 Key Trial References -- 9.2 Study Funding -- 9.3 Importance of Study -- 9.4 Study Design -- 9.5 Key Results -- 9.6 Conclusions from Original Reports -- 9.7 Strengths -- 9.8 Weaknesse.